772. In Vivo and In Vitro Characterization of ProvodineŽ, a Long Acting, Alcohol-Free Professional Antiseptic, Against Ebola Virus and Other Serious Viral, Bacterial and Fungal Pathogens
Session: Poster Abstract Session: Antimicrobial Agents: Novel Agents
Friday, October 9, 2015
Room: Poster Hall
  • IDWeek poster final.pdf (4.6 MB)
  • Background: Control of the spread of Ebola and other deadly pathogens is essential to the success of military and public health efforts wherever this virus or other Category A/B pathogens emerge. While many disinfectants may be available to control the spread of virus particles, there are no codified antiseptic products safe for use on skin and approved for use against Ebola and other Category A/B pathogens.  USAMRIID and Microdermis Corporation have partnered to develop, test, and deploy a new professional use antiseptic, Provodine, which was used by USAMRIID personnel deployed to West Africa as part of the international response to the recent Ebola outbreak.  Provodine was specifically formulated to provide a molecular barrier, which limits the penetration of the active ingredient, povidone-iodine (PVP-I), to the superficial epidermis while retaining and enhancing its antimicrobial activity.  

    Methods: To demonstrate the antimicrobial activity of Provodine, the product was tested in suspension time-kill assays against Ebola Zaire-95, Marburg, Lassa and MERS coronavirus.  Subsequently, skin surface killing was assessed using a pig skin model wherein the product was applied and then challenged with virus at specific time points after application.  Finally, the activity of the product on bacterial and fungal pathogens was assessed in two separate in-vitro systems (artificial skin using MRSA, A. baumanii and C. albicans and mature biofilm using MRSA, VRE, A. baumanii, S. pyogenes, P. aeruginosa, H. influenza and C. albicans).  

    Results: Provodine demonstrated both short-term killing of virus (> 3 log reductions in 30 seconds), as well as prolonged killing (>90%) of newly introduced virus for at least 12 hours after product application in the pig skin model.  In addition, Provodine was able to produce > 4 log reductions in freshly introduced bacterial and fungal CFU out to 9 hours after product application on artificial skin and > 4 log reductions in recoverable CFU when tested against mature biofilm.  Finally, confocal microscopic imaging of punch biopsies from human skin (normal volunteer) demonstrates the selective deposition of PVP-I in the epidermis.

    Conclusion: Provodine appears to be a superior professional antiseptic for use against both common pathogens, MDRO, and emerging pathogens of concern to the biodefense and infectious disease communities.

    Peter Lentini, MS1, Cary Retterer, MS2, Sina Bavari, PhD2 and John Cheronis, MD, PhD1, (1)Microdermis Corporation, Princeton, NJ, (2)US Army Research Institute of Infectious Diseases, Frederick, MD


    P. Lentini, Microdermis: Employee and Shareholder , Salary

    C. Retterer, None

    S. Bavari, None

    J. Cheronis, Microdermis: Employee and Shareholder , Salary

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.